Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment
Vancouver, British Columbia – September 14, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administration (FDA)
Read More »
September 14, 2021
Nova Mentis to Present at the H.C. Wainwright Global Investment Conference
Vancouver, British Columbia – September 9, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for chronic inflammatory disorders, is pleased to announce that it will present at the H.C. Wainwright 23rd Annual Global Investment
Read More »
September 9, 2021
Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes
Vancouver, British Columbia – September 7, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it is expanding its psilocybin research and development program to target obesity
Read More »
September 7, 2021
Nova Mentis Files Fragile X Orphan Drug Designation with European Medicines Agency
Vancouver, British Columbia – August 12, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has filed for orphan drug designation with the European Medicines Agency (EMA) for its propriety psilocybin
Read More »
August 12, 2021
Glow Acquires Strategic Equity Investment in Nova Mentis
TORONTO, Ontario -August 10, 2021 – Glow LifeTech Corp. (CSE: GLOW) (FSE: 9DO) (“Glow” or the “Company”), a biotech company focused on producing next-generation, science-backed natural ingredients, is pleased to announce a strategic investment into Nova Mentis1 (“Nova”). The Company purchased 854,000 shares in Nova at an average cost of $0.12 CAD. Nova Mentis Life Science Corp. is a Canadian-based biotechnology company
Read More »
August 11, 2021
Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics
Vancouver, British Columbia – July 29, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has filed a U.S. provisional patent application for a proprietary manufacturing process for the production of
Read More »
July 29, 2021